The trial is taking place at:
C

Cardiovascular Research Institute of Kansas, LLC | Wichita, KS

Veeva-enabled site

Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT)

Abbott logo

Abbott

Status

Enrolling

Conditions

Heart Valve Diseases
Degenerative Mitral Valve Disease
Functional Mitral Regurgitation
Mitral Valve Insufficiency
Mitral Insufficiency
Mitral Regurgitation
Cardiovascular Diseases
Valve Disease, Heart

Treatments

Device: Tendyne Mitral Valve System
Device: MitraClip System

Study type

Interventional

Funder types

Industry

Identifiers

NCT03433274
CS0004-P

Details and patient eligibility

About

Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort. Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.

Enrollment

958 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Symptomatic, moderate-to-severe or severe mitral regurgitation, or severe mitral annular calcification (MAC)
  • NYHA Functional Classification ≥ II (if Class IV, patient must be ambulatory)
  • The local site heart team determines that the subject has been adequately treated per applicable standards
  • Not a member of a vulnerable population

Exclusion criteria

  • Mitral valvular vegetation or mass
  • Left ventricular ejection fraction < 25%
  • Left ventricular end diastolic diameter > 7.0 cm
  • Prior surgical or interventional treatment of mitral valve involving implantation of prosthetic material
  • Aortic valve disease requiring surgery or transcatheter intervention
  • Severe tricuspid regurgitation or any tricuspid valve disease requiring surgery or transcatheter intervention
  • Any planned surgical / interventional procedure within 60 day prior to or following subject randomization
  • Subject undergoing hemodialysis due to chronic renal failure
  • Mitral pathoanatomy and left ventricular outflow tract anatomy deemed not suitable for Trial device implantation
  • Subjects with non-cardiac comorbidities that are likely to result in a life expectancy of less than 12 months

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

958 participants in 5 patient groups

Randomized Cohort - Treatment Group
Experimental group
Description:
Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
Treatment:
Device: Tendyne Mitral Valve System
Randomized Cohort - Control Group
Active Comparator group
Description:
Treatment of mitral regurgitation within commercially approved MitraClip system indications
Treatment:
Device: MitraClip System
Non-repairable Cohort
Experimental group
Description:
Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
Treatment:
Device: Tendyne Mitral Valve System
Severe Mitral Annular Calcification (MAC) Cohort
Experimental group
Description:
Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System
Treatment:
Device: Tendyne Mitral Valve System
Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP) Cohort
Experimental group
Description:
Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System after the completion of enrollment in the Severe MAC Cohort
Treatment:
Device: Tendyne Mitral Valve System

Trial contacts and locations

80

Loading...

Central trial contact

Kayla Dellefratte; Leslie Ornelas

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems